You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The MIT researchers said that the mutational signature could be used to identify people exposed to aflatoxin who are at risk of developing liver cancer.
A special thermal annealing process and graphene oxide structure may enable inexpensive manufacturing and use, particularly in resource-poor areas of the world.
The Broad Institute's lawyers used statements from Jennifer Doudna to undermine UC's case that one could expect CRISPR/Cas9 to work in eukaryotic cells.
The platform, called Seq-Well, is similar to droplet-based approaches but reports increased efficiency.
MIT President Rafael Reif speaks with the Los Angeles Times about the Trump administration travel ban and more.
In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.
The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.
Two Broad Institute teams, led by Eric Lander and Feng Zhang, respectively, have published new papers today in Science on new uses for lenti-CRISPR screens.
Researchers are making mutations in a cell's genome to mark it and later read out that information to create cell lineage maps and chemical interaction histories.
The method works by adding noise to database search results to confound algorithms that try to access private details about contributing individuals.
Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.
The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.
Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.